| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia |
|
Medicine details |
|
| Medicine name | ranibizumab (Lucentis®) |
| Formulation | 10 mg/ml solution for injection |
| Reference number | 1100 |
| Indication | Treatment of visual impairment due to choroidal neovascularisation secondary to pathologic myopia |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Eye |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 06/09/2013 |
| NICE guidance | TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia |